They also identified mutations that were not previously documented in aggressive meningiomas, including CASS4 and CMKLR1, and the less frequently reported MUC3A, ALDH1A3, and HOXA1. In a similar way, stratifying patients by a combined genome-epigenome status could be a feasible alternative in future screening for MM. This evidence concerns the gene MUC3A and Miyoshi myopathy.